Financials

	2022	2023
Net sales	4.85Cr 4.26Cr 3.96Cr 3.63Cr 6.82Cr 466.69Cr 6.93Cr 47Cr 18Cr 229.44Cr 18Cr 18Cr 793.3Cr	4.92Cr 4.32Cr 4.02Cr 3.68Cr 6.92Cr 473.45Cr 7.03Cr 48Cr 19Cr 232.77Cr 18Cr 18Cr 804.8Cr
Net income	-2.86Cr -2.51Cr -2.34Cr -2.15Cr -4.03Cr -275.75Cr -4.09Cr -28Cr -11Cr -135.57Cr -11Cr -11Cr -468.73Cr	-2.06Cr -1.81Cr -1.69Cr -1.55Cr -2.91Cr -198.69Cr -2.95Cr -20Cr -7.82Cr -98Cr -7.75Cr -7.58Cr -337.74Cr
Net Debt	1.15Cr 1.01Cr 93.99L 86.25L 1.62Cr 110.81Cr 1.65Cr 11Cr 4.36Cr 54Cr 4.32Cr 4.23Cr 188.36Cr	91.41L 80.29L 74.66L 68.51L 1.29Cr 88Cr 1.31Cr 8.87Cr 3.46Cr 43Cr 3.43Cr 3.36Cr 149.63Cr

Company Profile

November 26, Inc., formerly BIOLASE, Inc., is not engaged in any business activities. The Company has no assets.

Employees

Sector

27/25/27	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/25/19	EnVVeno Medical Names Jennifer Bright CFO	MT
05/25/05	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25/25/25	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
21/25/21	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
18/25/18	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
14/25/14	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
29/25/29	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
14/25/14	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
13/25/13	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
08/25/08	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
23/24/23	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
15/24/15	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

01/24/01	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
31/23/31	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
20/23/20	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
20/22/20	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

14/25/14	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
08/24/08	Biolase: Q3 Earnings Snapshot	AQ
08/24/08	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
02/24/02	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
09/24/09	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	10/09/2025
Steven Sandor COO	Chief Operating Officer	46	06/07/2022
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	01/10/2016

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	01/09/2017
Kathleen O'Loughlin BRD	Director/Board Member	75	16/08/2021
Martha Somerman BRD	Director/Board Member	-	16/08/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE INC	-6.39%	-2.55%	-	-	36
BOXABL INC.	-23.85%	-26.51%	-38.17%	-	1.62TCr
CHURCHILL CAPITAL CORP XI	-5.00%	-5.46%	-	-	80Cr
DEEP FISSION, INC.	-3.84%	-3.66%	-	-	64Cr
CENTIEL AG	+1.22%	+19.06%	+298.80%	-66.05%	65Cr
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	+0.20%	-	-	64Cr
CANTOR EQUITY PARTNERS IV, INC.	+0.38%	+0.62%	-	-	60Cr
BAIN CAPITAL GSS INVESTMENT CORP.	+0.16%	+0.15%	-	-	60Cr
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	+0.52%	+0.69%	-	-	58Cr
Average	-4.08%	-3.37%	+130.31%	-66.05%	258.89Cr
Weighted average by Cap.	-18.90%	-26.29%	-25.11%	-66.05%